Quarterly report pursuant to Section 13 or 15(d)

Earning (Loss) Per Share (Details)

v3.24.1.1.u2
Earning (Loss) Per Share (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Numerator:    
Net income (loss) for basic earnings per share $ 413,612 $ (14,138,665)
Adjustments to net income (loss) available to shareholders    
Change in fair value of SPA warrant liabilities (7,942,330) 0
Adjusted net loss for diluted earnings per share $ (7,528,718) $ (14,138,665)
Denominator:    
Weighted average shares used to compute basic EPS (in shares) 44,635,720 39,765,361
Dilutive effect of:    
Restricted and performance stock units (in shares) 434,562 0
SPA Warrants (in shares) 21,672,526 0
Diluted weighted average shares outstanding (in shares) 66,742,808 39,765,361
Basic earnings (loss) per share (in dollars per share) $ 0.01 $ (0.36)
Diluted loss per share (in dollars per share) $ (0.11) $ (0.36)
Anti-dilutive securities excluded from shares outstanding:    
Total anti-dilutive securities excluded from shares outstanding (in shares) 149,671,977 35,786,241
Stock options    
Anti-dilutive securities excluded from shares outstanding:    
Total anti-dilutive securities excluded from shares outstanding (in shares) 2,555,470 3,472,129
Restricted and performance stock units    
Anti-dilutive securities excluded from shares outstanding:    
Total anti-dilutive securities excluded from shares outstanding (in shares) 4,624,496 3,169,269
Warrants    
Anti-dilutive securities excluded from shares outstanding:    
Total anti-dilutive securities excluded from shares outstanding (in shares) 15,800,000 18,722,425
Earnout shares    
Anti-dilutive securities excluded from shares outstanding:    
Total anti-dilutive securities excluded from shares outstanding (in shares) 7,499,993 7,499,993
Convertible debt    
Anti-dilutive securities excluded from shares outstanding:    
Total anti-dilutive securities excluded from shares outstanding (in shares) 119,192,018 2,922,425